🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Nasopharyngeal Carcinoma (NPC)

"Xijiang Project" Screening Cohort for NPC NCT06787456n/a1 site📍 Zhuhai Ming-Yuan Chen · Tests: EBV antibodies test, EBV DNA test, epidemiological information survey, Clinical examinations for high-risk participants… Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma NCT04448522Phase 36 sites📍 Guangzhou📍 Guangzhou📍 Shaoguan Sun Yat-sen University · Tests: reduced dosage IMRT, conventional dosage IMRT Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma NCT05587543EARLY Phase 11 site📍 Shanghai Fudan University · Tests: PK Blood Collection, CAR, TCR An International Study on Pediatric Patients With Rare Tumors. NCT07072143n/a1 site📍 Padova Azienda Ospedaliera di Padova EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663Phase 2, Phase 31 site📍 Shanghai RenJi Hospital · Tests: [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4, [18F]F-RESCA-RT4 Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy NCT07232680n/a1 site📍 Taoyuan City Cheng-En Hsieh · Tests: Proton chemoradiotherapy, Photon chemoradiotherapy Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. NCT06059261Phase 21 site📍 Chongqing Chongqing University Cancer Hospital · Tests: Envafolimab and recombinant human endostatin combined with chemoradiotherapy Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC NCT06657690Phase 21 site📍 Zhuhai Sun Yat-sen University · Tests: Irinotecan liposome, S-1 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma NCT06976190Phase 31 site📍 Guangzhou Lepu Biopharma Co., Ltd. · Tests: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC NCT07331428Phase 21 site📍 Fuzhou Fujian Cancer Hospital · Tests: MRG003, Tislelizumab, Capecitabine 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma NCT07328854Phase 315 sites📍 Hefei📍 Fuzhou📍 Guangzhou Ming-Yuan Chen · Tests: Cisplatin-based induction chemotherapy, Full course of PD-1 monoclonal antibody, Reduced-dose radiotherapy to CTV2, Con… Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma NCT04778956Phase 37 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, salvage surgery Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response NCT06239727Phase 326 sites📍 Fuzhou📍 Xiamen📍 Dongguan Sun Yat-sen University · Tests: PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2), Reduced-dose Intensity-modulated radiotherapy, Conventional-… Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy NCT05892354NA20 sites📍 Fuzhou📍 Fuzhou📍 Guangzhou First Affiliated Hospital of Guangxi Medical University · Tests: Enteral immunonutrition, Standard enteral nutrition Adebrelimab and Chemoradiotherapy in High-risk LANPC NCT06349889Phase 24 sites📍 Xiamen📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Adebrelimab Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy NCT05674305Phase 31 site📍 Shanghai Fudan University · Tests: Radiotherapy, Cisplatin A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma. NCT06851247Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, Anlotinib, Gemcitabine, Cisplatin, radiation LDRT and Chemoimmunotherapy in NPC With Liver Metastasis NCT06788002Phase 28 sites📍 Changsha📍 Changsha📍 Changsha Hunan Cancer Hospital · Tests: Low-dose radiotherapy combine with chemoimmunotherapy Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma NCT05717790NA9 sites📍 Baise City📍 Baise City📍 Guilin Fourth Affiliated Hospital of Guangxi Medical University · Tests: Nimotuzumab, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment NCT04875611Phase 24 sites📍 Bialystok📍 Gdansk📍 Gliwice Maria Sklodowska-Curie National Research Institute of Oncol… · Tests: Opdivo Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Metastatic Nasopharyngeal Carcinoma NCT06886347Phase 11 site📍 Hangzhou Chen Xiaozhong · Tests: Penplimab Injection, Antitinib Hydrochloride Capsules, Gemcitabine Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy NCT06092957Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT, Standard-dose IMRT, Con… Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. NCT07781358Phase 21 site📍 Shanghai Hongmeng Yu · Tests: Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma NCT04453826Phase 36 sites📍 Guangzhou📍 Guangzhou📍 Shaoguan Sun Yat-sen University · Tests: Camrelizumab plus chemo-radiotherapy, Chemo-radiotherapy alone A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) NCT06241599Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: GP/PFLL+AK104, GP/PFLL+placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy